StockData
Filana Therapeutics, Inc. logo

Filana Therapeutics, Inc. (FLNA) company profile

FLNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$0.64+0.08 (+14.52%)

Close on Nov 20, 2026Market cap $30.98MP/E –Yield –

About Filana Therapeutics

Pharmaceutical Preparations, SIC 2834

Filana Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system disorders. The company's lead drug candidate is simufilam, a proprietary oral small molecule designed to modulate filamin A protein activity. Filana is studying simufilam specifically for the treatment of tuberous sclerosis complex-related epilepsy, a genetic condition that causes non-malignant tumors and frequent treatment-resistant seizures. While the company operates in pharmaceutical research and development, its prospective end users are individuals affected by central nervous system conditions and tuberous sclerosis complex.

The company is headquartered in Austin, Texas. Filana maintains exclusive worldwide rights and patent protections for simufilam across jurisdictions including the United States, Europe, Australia, Israel, Canada, and Japan. The company does not own or lease manufacturing facilities, choosing instead to outsource development, formulation, and drug substance production to third-party contract manufacturers such as Evonik Corporation. Research collaborations, preclinical evaluations, and patent licensing agreements have also been established with academic and scientific organizations.

Summary of the business section of Filana Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Filana Therapeutics, Inc.
Founded
1998
Headquarters
Austin, TX
Address
6801 N Capital Of Texas Highway, Building 1; Suite 300 78731
Phone
(512) 501-2444
Employees
17, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Austin, Texas

Stock & identifiers

Ticker
FLNA
Former tickers
SAVA until Oct 20, 2026; PTIE until Mar 29, 2019
Exchange
Nasdaq
IPO date
Jul 14, 2000
Shares outstanding
48M, Jul 27, 2026
Public float
$87.00M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-7 reverse, May 10, 2017
SEC CIK
1069530
CUSIP
14817C107
ISIN
US14817C1071
FIGI
BBG000BK9YW3
Share class FIGI
BBG001SCKXX9
LEI
529900XA0UG5JXABYF08
EIN
91-1911336

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Richard BarryPresident & CEO, Director1,955,947
Eric SchoenChief Financial Officer31,500
Robert Christopher CookChief Operating& Legal Officer135,300
Freda NassifChief Business Officer–
James William KupiecChief Medical Officer0
Robert Eugene Anderson JrDirector27,600
Jill M. QuigleyDirector–
Dawn Carter BirDirector–
Patrick J. Md Scannon PhdDirector1,000
Pierre GravierDirector–
Robert Z. GussinDirector10,617
Claude NicaiseDirector–
Donnell Michael J. ODirector65,812

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Mr Barbier
$0$0$824.50K$7–
FY2025
Mr Barry
$1.52M$1.33M$824.50K$7–
FY2024
Former PEO
$3.69M-$1.01M$3.58M$8–
FY2024
Mr Barbier
$3.69M-$1.01M$3.58M$8–
FY2024
Mr Barry
$16.73M$1.78M$3.58M$8–
FY2023$6.26M$7.56M$2.41M$76–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsTotalvs. prior year
Richard J. Barry
President and Chief Executive Officer
$675.00K$355.00K$490.04K$1.52M-91%
R. Christopher Cook
Chief Operating and Legal Officer (2)
$463.98K$215.00K$140.01K$818.99K-75%
Eric J. Schoen
Chief Financial Officer
$475.00K$215.00K$140.01K$830.01K-78%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 17 full-time employees and 3 employees who devote a portion of their professional time to the Company.”

Corporate history

Events identified from SEC filings

DateEventDetails
Sep 18, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 19, 2026Name changeName changed from CASSAVA SCIENCES INC to Filana Therapeutics, Inc.
Aug 8, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 3, 2024DelistingNotice of delisting from exchange (Form 25)
Jan 3, 2024ListingRegistration of securities on an exchange (Form 8-A)
Mar 25, 2019Name changeName changed from PAIN THERAPEUTICS INC to CASSAVA SCIENCES INC
May 1, 2018Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 16, 2018Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 18, 2016Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)

See a number that looks wrong?